Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis - Blauvelt, Andrew; Kircik, Leon; Schlesinger, Todd; Pierce, Evangeline; Burge, Russel; Behling, Michael; Atwater, Amber Reck; ElMaraghy, Hany; Armstrong, April (Journal of Dermatological Treatment, 2025)